Hyaluronan Conjugates for Neurodegenerative Disease Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases such as Alzheimer's, Parkinson's, and multiple sclerosis primarily focus on symptom mitigation and disease progression delay, with limited effectiveness and significant side effects, necessitating a more robust therapeutic approach.
Innovation Solution
Development of hyaluronan conjugates comprising hyaluronic acid, sex hormones (like estrone, estradiol, and testosterone), and linkers (such as amino acids or dicarboxylic acids) that are administered via various routes to target neurodegenerative diseases, potentially offering improved therapeutic efficacy with reduced side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional drugs (donepezil, galantamine, rivastigmine, levodopa, elldopa, amantadine) are used to treat neurodegenerative diseases, then symptom mitigation and disease progression delay are achieved, but serious side effects occur and life quality remains disappointing
Solution Approach 1:
The patent employs a composite therapeutic approach by combining hyaluronan (a biomaterial) with sex hormones (estrone, estradiol, estriol, testosterone, or 11-deoxycorticosterone) to create a conjugate system. This composite structure allows the hyaluronan carrier to deliver the active hormone components while potentially reducing their systemic side effects, thereby improving the therapeutic index for neurodegenerative diseases
Solution Approach 2:
Hyaluronan serves as an intermediary carrier that delivers sex hormones to target tissues. The hyaluronan-conjugate system acts as a mediator between the administered drug and the target receptors, potentially enabling more selective delivery to neural tissues and reducing off-target side effects while maintaining therapeutic effectiveness
2Duration of action of stationary object
If current treatments are used to defer disease progression, then survival rate increases, but life quality remains disappointing due to limited effectiveness
Solution Approach 1:
The patent utilizes different sex hormones (estrone, estradiol, estriol, testosterone, 11-deoxycorticosterone) with varying pharmacological properties and durations of action. By selecting specific hormones and adjusting their conjugation to hyaluronan, the therapeutic parameters can be optimized to achieve both prolonged disease progression delay and improved life quality through better symptom management
Data Source
AI summary
Disclosed herein is a method of using a hyaluronan conjugate, which includes a hyaluronic acid (HA), a sex hormone, and a linker for coupling one of the disaccharide units of the HA and the sex hormone. The hyaluronan conjugates are used in treating neurodegenerative diseases.